BioSpace News Archive

Orthobond announced the appointment of Frank P. Cammisa, MD, as the company’s Chief Medical Officer.

Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today at the 2021 San Antonio Breast Cancer Symposium (SABCS), presented encouraging clinical data on samuraciclib (CT7001).

Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of YH004 (anti-4-1BB monoclonal antibody, mAb) (No. YH004002) in Australia.

Halozyme Therapeutics, Inc. announced that its Board of Directors has approved a new share repurchase program effective immediately, which authorizes the Company to purchase up to $750 million of the Company’s outstanding common stock over the next three years.

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody.

Increasing use of holographic devices to understand complexity of diseases, rising healthcare investments and expenditures, and technological advancements in holographic technology are key factors driving market growth.

Increasing prevalence of cancer and increasing use of proton therapy for cancer treatment are some key factors driving market revenue growth.

Major factors driving market revenue growth include increasing use of stem cells to treat various diseases, increasing stem cell-based research activities, and growing funding in stem cell-based research.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, reported financial results for the quarter ended September 30, 2021.

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 83,400 shares of the Company’s common stock at an exercise price per share of $44.17, which was the closing price on December 8, 2021.